Comparative Pharmacology
Head-to-head clinical analysis: AMINOHIPPURATE SODIUM versus ARIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOHIPPURATE SODIUM versus ARIDOL.
AMINOHIPPURATE SODIUM vs ARIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminohippurate sodium is a diagnostic agent used to measure effective renal plasma flow (ERPF) by competitive inhibition of tubular secretion of para-aminohippurate (PAH) via organic anion transporters (OAT1 and OAT3) in the proximal tubule, allowing clearance calculations.
Aridol (mannitol) is an osmotic agent that, when inhaled, increases airway osmolarity, leading to release of mediators from mast cells and eosinophils, causing bronchoconstriction in susceptible individuals. It is used as a bronchial challenge test to assess airway hyperresponsiveness.
For measurement of effective renal plasma flow (ERPF): 0.2 mL/kg of a 20% solution (40 mg/kg) administered intravenously over 1-2 minutes, followed by continuous intravenous infusion of 0.5 mL/min of a solution containing 4.5 g aminohippurate sodium in 500 mL normal saline (9 mg/mL) to maintain stable plasma levels.
For bronchial challenge testing: inhaled dose of 5 mg (one vial) via nebulizer, single administration.
None Documented
None Documented
Terminal elimination half-life is approximately 0.5–1.0 hour; used to measure effective renal plasma flow (ERPF).
16.1 ± 8.5 minutes in healthy adults. Clinical context: Short half-life allows repeated provocative testing within 2–3 hours.
Primarily renal: ~90% excreted unchanged by tubular secretion; <5% fecal.
Primarily renal excretion of unchanged mannitol. Approximately 80% of the administered dose is excreted unchanged in urine within 12 hours; minor biliary/fecal elimination (<5%).
Category C
Category C
Diagnostic Agent
Diagnostic Agent